Bacterial Infections Antimicrobial Resistance & Stewardship Research & Innovation

Uncomplicated UTIs: Antibiotics lasting over 7 days tied to adverse events

Share

Female patients with uncomplicated urinary tract infections who received antibiotic treatment lasting eight days or longer had a 20% higher rate of treatment-related adverse events than those treated for five to seven days, according to a study presented at IDWeek 2026.

The retrospective study of 57,448 female patients in the United States found that extended treatment was associated with a significantly higher rate of adverse events overall (rate ratio, 1.20; 95% confidence interval, 1.09-1.32; P < 0.001). 

Uncomplicated urinary tract infections are a leading reason for antibiotic use in the United States. Although shorter treatment durations are recommended for several agents, prescribing practices vary and can result in prolonged antibiotic exposure, according to Amy G. Edgecomb, PharmD, MPH, and colleagues.

They evaluated the association between treatment duration and adverse events using electronic health records from Optum's de-identified Market Clarity database covering May 2023 through March 2025.

The study included female patients ages 12 and older who had symptomatic uncomplicated urinary tract infections, received an antibiotic prescription within five days of diagnosis and had at least 12 months of electronic health record activity before their first antibiotic prescription following diagnosis.

Of the 57,448 eligible patients, 17,867 (31.1%) received extended treatment lasting at least eight days, while 39,581 (68.9%) received treatment lasting five to seven days.

Patients receiving extended treatment were generally older than those receiving shorter courses, with a mean age of 55.1 years compared with 52.3 years, and had more coexisting medical conditions.

Nitrofurantoin was the most commonly prescribed antibiotic in both groups, accounting for 39% of prescriptions in the extended-treatment group and 46.1% in the shorter-treatment group. Other commonly prescribed agents included beta-lactams, trimethoprim-sulfamethoxazole and fluoroquinolones.

Treatment duration was categorized during a seven-day period beginning with the first antibiotic prescription, and treatment-related adverse events were assessed for up to 90 days after that period. The researchers used propensity score weighting to account for differences in patient characteristics when comparing the groups.

In addition to the higher overall rate of adverse events, extended treatment was associated with higher rates of gastrointestinal events (rate ratio, 1.42; 95% confidence interval, 1.24-1.63), genitourinary events (1.52; 95% confidence interval, 1.25-1.84), endocrine events (1.40; 95% confidence interval, 1.02-1.91) and hypersensitivity events (2.38; 95% confidence interval, 1.28-4.40).

“Extended ABX treatment duration was associated with higher rates of TRAEs compared with appropriate treatment duration, highlighting the importance of aligning ABX therapy duration with antimicrobial stewardship guidelines to optimize patient safety,” noted Edgecomb, director of U.S. Real-World Evidence and Health Outcomes Research at GSK in Collegeville, Pennsylvania, and colleagues.

The study was funded by GSK. Several authors are GSK employees, and some reported stock ownership. Analysis Group received funding from GSK to conduct the study. One co-author also reported research support from Pfizer.